WuXi Biologics gains FTSE4Good recognition for sixth consecutive year

Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184

DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development

AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance

CSL reports positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children with HAE

Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101

Harbour BioMed and Sinopharm establish innovation R&D consortium

argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102

AstraZeneca reports positive Phase III survival results for Sone-Ve in advanced gastric cancers

Faron reports encouraging first overall survival data from BEXMAB frontline HR-MDS trial

NewAmsterdam Pharma and Menarini Group report positive CHMP opinion for obicetrapib monotherapy and obicetrapib/ezetimibe combination

CHMP backs Gilead's Trodelvy-Keytruda combination for first-line metastatic triple-negative breast cancer

Active Biotech doses first patient in amended tasquinimod myelofibrosis study

Ipsen's Phase III BOLD trial misses primary endpoint in biliary atresia

Sanofi ends atopic dermatitis development for amlitelimab